

# Cirralto Limited

ACN 099 084 143

## Prospectus

For an offer of:

- (a) up to 132,951,740 Consideration Shares to the Invigo Vendors (or their respective nominees) in consideration for the Acquisition (**Vendor Offer**); and
- (b) up to 10,000 Shares at an issue price of \$0.058 per Share to raise up to \$580 (before expenses) for the purpose of removing trading restrictions on Shares issued by the Company prior to the Closing Date (**Cleansing Offer**),

(together, the **Offers**).

**The purpose of the Vendor Offer under this Prospectus is to make the offer of the Consideration Shares to the Invigo Vendors under a disclosure document and to complete the Acquisition. The Vendor Offer and the issue of Consideration Shares under this Prospectus is strictly limited to the Invigo Vendors only.**

**This Prospectus has also been prepared for the purposes of section 708A(11) of the Corporations Act to remove any trading restrictions on the sale of Shares issued by the Company prior to the Closing Date.**

### **Important Notice**

This is an important document and should be read in its entirety.

This Prospectus is a transaction-specific prospectus issued in accordance with section 713 of the Corporations Act. If you have any queries about any part of the Prospectus, please contact your professional adviser without delay. The Shares offered by this Prospectus should be considered speculative.

For personal use only

# Corporate Directory

---

## Directors

Peter Richards (Non-Executive Chairman)  
Adrian Floate (Managing Director)  
Stephen Dale (Non-Executive Director)  
Howard Digby (Non-Executive Director)

## Company Secretary

Justyn Stedwell

## Registered Office

Suite 103, Level 1, 2 Queen Street  
Melbourne, VIC 3000

Email: [shareholders@cirralto.com.au](mailto:shareholders@cirralto.com.au)  
Website: [www.cirralto.com.au](http://www.cirralto.com.au)

## ASX Code

CRO (Shares)  
CROO (Listed Options)

## Share Registry\*

Automatic Registry Services  
Level 5, 126 Phillip Street  
Sydney, NSW 2000

Telephone: 1300 288 664 (within Australia)  
or +61 2 9698 5414 (outside Australia)

## Solicitors

Nova Legal  
Level 2, 50 Kings Park Road  
West Perth WA 6005

## Auditor\*

Nexia Perth Audit Services Pty Ltd  
Level 3, 88 William Street  
Perth, WA 6000

\* These parties are included for information purposes only. They have not been involved in the preparation of this Prospectus.

## Contents

---

IMPORTANT INFORMATION .....	4
TIMETABLE AND IMPORTANT DATES .....	6
1. DETAILS OF THE OFFERS .....	7
2. RISK FACTORS .....	12
3. PURPOSE AND EFFECT OF THE OFFERS .....	16
4. RIGHTS ATTACHING TO SHARES .....	18
5. ADDITIONAL INFORMATION .....	20
6. DIRECTOR'S CONSENT .....	29
7. DEFINITIONS .....	30
Annexure A – Pro-Forma Statement of Financial Position .....	32

For personal use only

# IMPORTANT INFORMATION

---

## GENERAL

This Prospectus is dated 22 July 2021 and was lodged with ASIC on that date. Neither ASIC nor ASX, nor any of their officers, take any responsibility for the contents of this Prospectus.

This Prospectus expires 13 months from the date it was lodged with ASIC. No securities will be issued on the basis of this Prospectus later than 13 months after the date of this Prospectus. An application will be made to ASX within 7 days after the date of this Prospectus for the quotation of the Shares the subject of this Prospectus.

In preparing this Prospectus, regard has been had to the fact that the Company is a disclosing entity for the purposes of the Corporations Act and that certain matters may reasonably be expected to be known to investors and their professional advisers. This Prospectus is issued pursuant to section 713 of the Corporations Act. Section 713 allows the issue of a more concise prospectus in relation to an offer of continuously quoted securities (as defined in the Corporations Act). This Prospectus is intended to be read in conjunction with the publicly available information in relation to the Company which has been notified to ASX and does not include all information that would be included in a prospectus for an initial public offering.

This document is important and it should be read in its entirety. The Shares to be issued pursuant to this Prospectus should be viewed as a speculative investment and investors should refer to Section 2 for details of certain risk factors which are considered to be relevant for the purposes of the Offers. Investors should consult their stockbroker, solicitor, accountant or other professional adviser if necessary.

No person is authorised to give any information or to make any representation in relation to the Offers which is not contained in this Prospectus and any such information may not be relied upon as having been authorised by the Directors.

A copy of this Prospectus can be downloaded from the Company's website at [www.cirralto.com.au](http://www.cirralto.com.au). The offer constituted by an electronic version of this Prospectus is only available to persons receiving an electronic version of this Prospectus within Australia. A hard copy of this Prospectus may be obtained by contacting the Company.

A number of terms and abbreviations used in this Prospectus have defined meanings set out in Section 7.

## APPLICANTS OUTSIDE AUSTRALIA

The distribution of this Prospectus in jurisdictions outside of Australia may be restricted by law and therefore persons who come into possession of this Prospectus should seek advice on and observe any such restrictions. Any failure to comply with any such restrictions may constitute a violation of the applicable securities law.

This Prospectus does not, and is not intended to, constitute an offer of securities in any jurisdiction where, or to any person to whom, it would be unlawful to make such an offer or issue. This Prospectus has not been, nor will it be lodged, filed or registered with any regulatory authority under the securities laws of any other country. Refer to Section 1.12 for more information.

## RISK FACTORS

Refer to Section 2 for details of the risks associated with an investment in the Company. As with any securities investment, there are risks associated with investing in the Company. Investors should be aware that an investment in the Company involves risks that may be greater than risks associated with an investment in some other companies. The principal risks that could affect the financial and

market performance of the Company are detailed in Section 2 of this Prospectus. The Shares on offer under this Prospectus should be considered speculative. Accordingly, before deciding to invest in the Company, investors should read this Prospectus in its entirety and should consider all factors in light of their individual circumstances and seek appropriate professional advice.

The Board aims to manage these risks by carefully planning its activities and implementing risk control measures. Some of the risks are, however, highly unpredictable and the extent to which they can be effectively managed is limited.

Risks of investing in the Company's existing assets and general risks are set out in Section 2 of this Prospectus.

Careful consideration should be given to all matters raised in this Prospectus and the relative risk factors prior to applying for Shares offered under this Prospectus. Investors should consider the risk factors described in Section 2, together with the information contained elsewhere in this Prospectus, before deciding whether to apply for Shares.

For personal use only

## TIMETABLE AND IMPORTANT DATES

---

EVENT	DATE
Lodgement of Prospectus with ASIC and ASX	22 July 2021
Opening Date of the Offers	22 July 2021
Closing Date of the Offers (5pm AEST)	29 July 2021

\* These dates are indicative only and subject to change. The Company reserves the right, subject to the Corporations Act, the ASX Listing Rules and other applicable laws, to vary the dates, including by extending the Closing Date.

For personal use only

# 1. DETAILS OF THE OFFERS

---

## 1.1 The Offers

### Vendor Offer

As announced to ASX on 5 July 2021, the Company entered into a binding share sale agreement (**Share Sale Agreement**) with Invigo Pty Ltd (ACN 622 520 450) (**Invigo**) and the shareholders of Invigo (**Invigo Vendors**) to acquire 100% of the issued capital of Invigo from the Invigo Vendors (**Acquisition**).

Pursuant to the Share Sale Agreement, the Company has agreed to issue 132,951,740 Shares (**Consideration Shares**) to the Invigo Vendors in consideration for the Acquisition. Accordingly, by this Prospectus, the Company invites the Invigo Vendors (or their respective nominees) to apply for a total of 132,951,740 Consideration Shares in accordance with their respective entitlements under the Share Sale Agreement. A summary of the material terms and conditions of the Share Sale Agreement is set out in Section 5.5.

The Vendor Offer will only be extended to the Invigo Vendors and only the Invigo Vendors may accept the Vendor Offer. A personalised Application Form will be issued to the Invigo Vendors (or their respective nominees), together with a copy of this Prospectus. No funds will be raised from the Consideration Shares as they are being issued as consideration for the Acquisition under the Share Sale Agreement.

The Consideration Shares offered under the Vendor Offer are of the same class and will rank equally in all respects with existing Shares on issue, other than in respect of voluntary escrow. A summary of the rights and liabilities attaching to the Shares is set out in Section 4.1 and details of the voluntary escrow restrictions applicable to a portion of the Consideration Shares is set out in Section 5.5.

Refer to the Company's announcement released to ASX on 5 July 2021 for further details regarding the Acquisition and Invigo.

### Cleansing Offer

The Cleansing Offer is an offer of up to 10,000 Shares at an issue price of \$0.058 per Share to raise up to \$580 (before expenses).

The Cleansing Offer will only be extended to specific parties on invitation from the Directors. Application Forms will only be provided by the Company to these parties.

All Shares issued under the Cleansing Offer will rank equally with existing Shares on issue. A summary of the rights and liabilities attaching to the Shares is set out in Section 4.1.

## 1.2 Purpose

### Vendor Offer

The purpose of the Vendor Offer is not to raise funds. Instead, its purpose is to issue the Consideration Shares to the Invigo Vendors under a disclosure document and to complete the Acquisition in accordance with the Share Sale Agreement. As at the date of this Prospectus, all conditions precedent to complete the Acquisition under the Share Sale Agreement have been satisfied.

### Cleansing Offer

The purpose of the Cleansing Offer is not to raise funds. Instead, its purpose is to remove trading restrictions on Shares issued without disclosure under Part 6D of the Corporations Act before the Closing Date.

Generally, section 707(3) of the Corporations Act requires that a prospectus is issued in order for a person to whom securities were issued without disclosure under Part 6D of the Corporations Act to offer those securities for sale within 12 months of their issue.

The Corporations Act provides an exception to section 707(3) where an entity issues a 'cleansing' notice under section 708A(5). The Company has been suspended from trading on the ASX for more than 5 days in the last 12 months and, as a result, is precluded from issuing a cleansing notice in accordance with section 708A(5) of the Corporations Act.

However, section 708A(11)(b) of the Corporations Act provides that a sale offer does not need disclosure to investors if:

- (a) the relevant securities are in a class of securities of the company that are already quoted on the ASX;
- (b) a prospectus is lodged with ASIC either:
  - (i) on or after the day on which the relevant securities were issued; or
  - (ii) before the day on which the relevant securities are issued and offer of securities that have been made under the prospectus are still open for acceptance on the day on which the relevant securities were issued; and
- (c) the prospectus is for an offer of securities issued by the company that are in the same class of securities as the relevant securities.

### **1.3 Underwriting**

The Offers are not underwritten.

### **1.4 Minimum Subscription**

There is no minimum subscription under the Offers.

### **1.5 Opening and Closing Dates**

The Offers will open for receipt of acceptances on **22 July 2021**.

The Offers will close at **5:00pm AEST on 29 July 2021**, or such later date as the Directors, in their absolute discretion and subject to compliance with the Listing Rules, may determine.

### **1.6 Applications**

Applications for Shares offered under this Prospectus must only be made by investors at the direction of the Company and must be made using the Application Form accompanying this Prospectus. The Offers are only available to those who are personally invited to accept the Offers. Accordingly, Application Forms will only be provided by the Company to these parties.

Only the Invigo Vendors (or their respective nominees) may accept the Vendor Offer. The Company will only provide an Application Form in relation to the Vendor Offer to the Invigo Vendors, together with a copy of this Prospectus. The Invigo Vendors are not required to pay any funds with the Application Form in respect of the Consideraiton Shares as they are being



issued in consideration for the Acquisition. Accordingly, no funds will be raised pursuant to the Vendor Offer.

The Company may determine in its discretion whether to accept any or all Applications under the Cleansing Offer. Payment for the Shares under the Cleansing Offer must be made in full at the issue price of \$0.058 per Share.

Completed Application Forms, together with application monies (if applicable), must be received by the Company prior to the Closing Date. Application Forms should be delivered, and payment made, to the Company in accordance with the instructions on the Application Form.

## **1.7 Capital raising fees**

No capital raising fees will be paid in relation to applications under the Offers.

## **1.8 ASX Listing**

Application for Official Quotation of the Shares issued pursuant to this Prospectus will be made within 7 days after the date of this Prospectus. If approval is not obtained from ASX before the expiration of 3 months after the date of issue of the Prospectus (or such period as varied by the ASIC), the Company will not issue any Shares and will repay all application monies for the Shares within the time prescribed under the Corporations Act, without interest.

The fact that ASX may grant Official Quotation to the Shares is not to be taken in any way as an indication of the merits of the Company or the Shares offered under this Prospectus.

## **1.9 Issue of Shares**

The issue of Shares will take place in accordance with the timetable set out at the commencement of this Prospectus and otherwise in accordance with the ASX Listing Rules. Application monies (if applicable) will be held in a separate subscription account until issue. This account will be established and the application monies will be kept by the Company in trust for each Applicant. Any interest earned on the application monies will be for the benefit of the Company and will be retained by the Company irrespective of whether the issue takes place and each Applicant waives the right to claim any interest.

The Directors will determine the recipients of all Shares offered under this Prospectus. The Directors reserve the right to reject any application or to allocate any Applicant fewer Shares than the number applied for.

Where the number of Shares issued is less than the number applied for, the surplus monies (if any) will be returned by cheque as soon as practicable after the Closing Date. Where no issue is made, the amount tendered on application will be returned in full by cheque as soon as practicable after the Closing Date. Interest will not be paid on monies refunded.

## **1.10 CHESS and Issuer Sponsorship**

The Company operates an electronic CHESS sub-register and an electronic issuer sponsored sub-register. These two sub-registers make up the Company's register of securities. The Company will not issue certificates to investors. Rather, holding statements (similar to bank statements) will be dispatched to investors as soon as practicable after issue.

Holding statements will be sent either by CHESS (for new investors who elect to hold their securities on the CHESS sub-register) or by the Company's Share Registry (for new investors who elect to hold their securities on the Issuer sponsored sub-register). The statements will set out the number of Shares issued under the Prospectus and provide details of a Holder

Identification Number (for new investors who elect to hold their securities on the Chess sub-register) or Security holder Reference Number (for new investors who elect to hold their securities on the issuer sponsored sub-register). Updated holding statements will also be sent to each new investor following the month in which the balance of their holding of Securities changes, and also as required by the Listing Rules or the Corporations Act.

## 1.11 Risks

As with any securities investment, there are risks associated with investing in the Company. The principal risks that could affect the financial and market performance of the Company are detailed in Section 2 of this Prospectus. The Shares on offer under this Prospectus should be considered speculative. Accordingly, before deciding to invest in the Company, investors should read this Prospectus in its entirety and should consider all factors in light of their individual circumstances and seek appropriate professional advice.

## 1.12 Applicants outside Australia

The distribution of this Prospectus outside of Australia may be restricted by law. This Offer does not, and is not intended to, constitute an offer in any place or jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer or to issue this Prospectus.

Residents of countries outside Australia should consult their professional advisers as to whether any government or other consents are required, or whether any formalities need to be observed should they wish to make an application to take up Shares on the basis of this Prospectus. The return of a duly completed Application Form will be taken to constitute a representation and warranty that there has been no breach of such laws and that all approvals and consents have been obtained.

### ***United Kingdom***

Neither this document nor any other document relating to the Offers has been delivered for approval to the Financial Conduct Authority in the United Kingdom (**UK**) and no prospectus (within the meaning of Section 85 of the Financial Services and Markets Act 2000, as amended (**FSMA**)) has been published or is intended to be published in respect of the Shares.

The Shares may not be offered or sold in the UK by means of this document or any other document, except in circumstances that do not require the publication of a prospectus under Section 86(1) of the FSMA. This document is issued on a confidential basis in the UK to "qualified investors" (within the meaning of Article 2(e) of the Prospectus Regulation (2017/1129/EU), replacing Section 86(7) of the FSMA). This document may not be distributed or reproduced, in whole or in part, nor may its contents be disclosed by recipients, to any other person in the UK.

Any invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) received in connection with the issue or sale of the Shares has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the UK in circumstances in which Section 21(1) of the FSMA does not apply to the Company.

In the UK, this document is being distributed only to, and is directed at, persons: (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (FPO); (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO; or (iii) to whom it may otherwise be lawfully communicated (together "**relevant**

persons"). The investment to which this document relates is available only to relevant persons. Any person who is not a relevant person should not act or rely on this document.

### **1.13 Taxation**

It is the responsibility of all persons to satisfy themselves of the particular taxation treatment that applies to them by consulting their own professional tax advisers. Taxation consequences will depend on particular circumstances. Neither the Company nor any of its officers accept any liability or responsibility in respect of the taxation consequences of the matters referred to above or any other taxation consequences connected with an investment in the Securities of the Company.

### **1.14 Privacy Disclosure**

Persons who apply for Shares pursuant to this Prospectus are asked to provide personal information to the Company, either directly or through the Share Registry. The Company and the Share Registry collect, hold and use that personal information to assess applications for securities to provide facilities and services to Shareholders, and to carry out various administrative functions. Access to the information collected may be provided to the Company's agents and service providers and to ASX, ASIC and other regulatory bodies on the basis that they deal with such information in accordance with the relevant privacy laws. If the information requested is not supplied, applications for Shares will not be processed. In accordance with privacy laws, information collected in relation to specific Applicants can be obtained by that Applicant through contacting the Company or the Share Registry.

### **1.15 Enquiries**

This document is important and should be read in its entirety. Persons who are in any doubt as to the course of action to be followed should consult their stockbroker, solicitor, accountant or other professional adviser without delay.

If you have any questions regarding the Offer, please contact the Company Secretary on +61(0) 3 8395 5446, from 8.30am to 5.00pm AEST, Monday to Friday.

## 2. RISK FACTORS

---

### 2.1 Introduction

The Shares offered under this Prospectus should be considered speculative because of the nature of the Company's business.

Whilst the Directors recommend that investors take up their entitlement to Shares, there are however numerous risk factors involved. Some of these risks can be mitigated by the use of safeguards and appropriate systems and controls, but some are outside the control of the Company and cannot be mitigated. Accordingly, an investment in the Company carries no guarantee with respect to the payment of dividends, return of capital or price at which the Securities will trade.

The following is a summary of the more material matters to be considered and should be read in conjunction with specific matters referred to in the Company's announcements and reports. However, the summary is not exhaustive and potential investors should examine the contents of this Prospectus in its entirety and consult their professional advisors before deciding whether to apply for the Shares.

### 2.2 Company specific

#### (a) Acquisition Risk

As part of its business strategy, the Company may make acquisitions of, or significant investments in, complementary companies or products. Any such transactions will be accompanied by risks commonly encountered in making such acquisitions.

#### (b) Dilution Risk

As at the date of this Prospectus (and prior to the issue of Consideration Shares pursuant to the Share Sale Agreement), the Company has 2,951,078,504 Shares and 613,444,107 Options on issue. Assuming no other Securities are issued, the number of Shares on issue will increase to 3,084,030,244 following completion of the Acquisition which means that the existing Shareholders will retain approximately 95.7% of the Company's issued Share capital and the Invigo Vendors will hold approximately 4.3% of the Company's issued Share capital.

There is a risk that the interests of Shareholders will be diluted as a result of future capital raisings that maybe required in order to fund the future development of the Company.

#### (c) Competition

Industries in which the Company, its subsidiaries and business partners operate are subject to technological change and competition. The Company, its subsidiaries and business partners face competition from other organisations, many of which may have significantly greater financial, technical and marketing resources than the Company. The Company, its subsidiaries and business partners have faced and are expected to continue to face, additional competition from existing competitors and from new entrants into its markets. Increased competition could result in margin reductions, lower customer numbers, under-utilisation of employees and/or contractors, reduced operating margins and loss of market share. Any of these occurrences could adversely affect the Company's business, operating results and financial condition.

#### (d) Dependence on Key Customers and Business Partners

The Company's business is reliant on business relationships with a number of key customers and/or business partners. A material proportion of the Company's future revenues are expected to be generated from such relationships with key customers and/or business partners. Loss or termination of key customers and/or business partnerships for any reason may have a significant adverse impact on the business, revenues and profitability of the Company.

(e) **Speculative Investment**

Shareholders should consider that the investment in the Company is speculative. The new Shares to be issued pursuant to this Prospectus carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those new Shares. Neither the Company nor the Directors warrant the future performance of the Company or any return on an investment in the Company.

(f) **Trading in new Shares may not be liquid**

There may be relatively few potential buyers or sellers of the new Shares on ASX at any time. This may increase the volatility of the market price of the new Shares. It may also affect the prevailing market price at which Shareholders are able to sell their new Shares. This may result in Shareholders receiving a market price for their new Shares that is less or more than the price that Shareholders paid.

(g) **Additional requirements for capital**

Additional funding will be required by the Company to effectively implement its business and operations plans in the future, to take advantage of opportunities for acquisitions, joint ventures or other business opportunities, and to meet any unanticipated liabilities or expenses which the Company may incur. Further additional financing will be required if the Board determines to accelerate the development of the Company's technology.

The Company may seek to raise further funds through equity or debt financing, joint ventures, licensing arrangements, production sharing arrangements or other means. Failure to obtain sufficient financing for the Company's activities and future projects may result in delay and indefinite postponement of activities. There can be no assurance that additional finance will be available when needed or, if available, the terms of the financing might not be favourable to the Company and might involve substantial dilution to Shareholders. Failure to gain funding as and when required may result in the Company being unable to finance its operations and ultimately being unable to operate as a going concern.

(h) **Economic Risks**

The Company and its subsidiaries are affected by general business cycles and general economic conditions, including but not limited to movements in interest and inflation rates, currency exchange rates, disposable income levels and consumer sentiment. These factors may have an adverse effect on the Company's earnings.

(i) **Market Conditions**

The market price of Shares can fall as well as rise and may be subject to varied and unpredictable influences on the market for equities in general. Share market conditions may affect the value of the Company's shares regardless of the Company's operating performance. Share market conditions are affected by many factors such as:

- (i) general economic outlook;
- (ii) interest rates and inflation rates;
- (iii) currency fluctuations;
- (iv) changes in investor sentiment toward particular market sectors;
- (v) the demand for, and supply of, capital; and
- (vi) terrorism or other hostilities.

(j) **Foreign Investment Risk**

The Company may operate in foreign jurisdictions. As a result, the Company may be subject to political, economic and other uncertainties including but not limited to foreign exchange restrictions, currency fluctuation, royalty and tax increases and other risks arising out of foreign government sovereignty over the areas in which the Company's operations may be conducted.

(k) **Reliance on Key Personnel**

The Company's success will depend in part on the continued services of its key contractors. The loss of services of one or more of the Company's key contractors could have a material adverse effect on the Company's business, operating results and financial condition. This risk is addressed in part by the existence of service contracts with executives and senior management. The Company does not have, nor does it intend to take out, key man insurance in respect of any of its key contractors.

(l) **Regulatory Changes**

Changes in government policies in any country, in particular Australia, may affect the Company's revenues and profitability and the value of an investment in the Company.

(m) **Litigation**

The Company may be exposed to litigation that may materially adversely affect the financial position of the Company and could negatively impact the Company through increased costs and payments for damages.

(n) **The Company does not expect to declare any dividends in the foreseeable future**

The Company does not anticipate declaring or paying any dividends to Shareholders in the foreseeable future. Consequently, investors may need to rely on sales of their securities to realise any future gains on their investment.

(o) **If the Company's goodwill or intangible assets become impaired, it may be required to record a significant charge to earnings**

Under Generally Accepted Accounting Principles, the Company reviews its intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill is required to be tested for impairment at least annually.

## 2.3 General Risks

### (a) General Economic Climate

The future prospects of the Company's business may be affected by circumstances and external factors beyond the Company's control. Financial performance of the Company may be affected by a number of business risks that apply to companies generally and may include economic, financial, market or regulatory conditions.

Factors such as inflation, currency fluctuation, interest rates and supply and demand have an impact on operating costs and stock market prices. The Company's future revenues and securities price may be affected by these factors which are beyond the Company's control.

### (b) Changes in Legislation and Government Regulation

Government legislation in Australia or any other relevant jurisdiction, including changes to the taxation system, may affect future earnings and relative attractiveness of investing in the Company. Changes in government policy or statutory changes may affect the Company and the attractiveness of an investment in it.

### (c) Share market Conditions

The market price of the Company's securities may be subject to varied and unpredictable influences on the market for equities in general and resources stocks in particular.

### (d) Coronavirus (COVID-19)

The outbreak of the coronavirus pandemic (COVID-19) is impacting on global economic markets. The nature and the extent of the effect of the outbreak on the performance of the Company remains unknown. The Company's Share price may be adversely affected in the short to medium term by the economic uncertainty caused by COVID-19. Further, any government or industry measures taken in response to COVID-19 may adversely impact the Company's operations and are likely to be beyond the control of the Company. The Directors are monitoring the situation closely and have considered the impact of COVID-19 on the Company's business and financial performance. With the situation continually evolving, the consequences are therefore inevitably uncertain at this point in time. If any of COVID-19 impacts appear material prior to the close of the Offer, the Company will inform investors under a supplementary Prospectus.

## 2.4 Speculative investment

The above list of risk factors ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company. The above factors, and others not specifically referred to above, may in the future materially affect the financial performance of the Company and the value of the Shares offered under this Prospectus.

Therefore, the Shares carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those Shares.

Potential investors should consider that the investment in the Company is speculative and should consult their professional advisers before deciding whether to apply for Shares pursuant to this Prospectus.

### 3. PURPOSE AND EFFECT OF THE OFFERS

#### 3.1 Purpose of the Offers

As set out in Section 1.2, the primary purpose of this Prospectus is not to raise funds. Instead its purpose is to:

- (a) issue the Consideration Shares to the Invigo Vendors in satisfaction of the Company's obligations under the Share Sale Agreement and to complete the Acquisition; and
- (b) remove trading restrictions on Shares issued by the Company without disclosure under Part 6D of the Corporations Act prior to the Closing Date (including prior to the date of this Prospectus).

As the Consideration Shares are being issued as consideration for the Acquisition, no funds will be raised from the Consideration Shares.

A nominal amount of \$580 may be raised under the Cleansing Offer (before costs). The funds raised from the Cleansing Offer (if any) will be applied towards the expenses of the Offers. Refer to Section 5.11 for details of the estimated expenses of the Offers.

#### 3.2 Effect on Capital Structure

The effect of the Offers on the capital structure of the Company (assuming all Shares and offered under this Prospectus are issued and no other Securities are issued) is set out below.

Security	Number
<b>Shares<sup>1</sup></b>	
Shares on issue as at the date of this Prospectus	2,951,078,504 <sup>2</sup>
Consideration Shares to be issued pursuant to the Vendor Offer	132,951,740 <sup>3</sup>
Shares to be issued pursuant to the Cleansing Offer	10,000
<b>Total Shares on issue on completion of the Offers</b>	<b>3,084,040,244<sup>4</sup></b>
<b>Options</b>	
Options on issue as at the date of this Prospectus:	
Listed Options exercisable at \$0.025 on or before 28 July 2023	528,110,774
Unlisted Options exercisable at \$0.045 on or before 30 June 2022	27,000,000
Unlisted Options exercisable at \$0.04 on or before 28 February 2022	3,833,333
Unlisted Options exercisable at \$0.025 on or before 28 July 2023	4,500,000
Unlisted Options exercisable at \$0.135 on or before 2 March 2024	50,000,000
<b>Total Options on issue on completion of the Offer</b>	<b>613,444,107</b>

Notes:



- 1 The rights and liabilities attaching to the Shares are summarised in Section 4.1.
- 2 200,893,772 Shares are subject to escrow until 2 June 2022.
- 3 A portion of the Consideration Shares will be subject to voluntary escrow for the periods outlined below:
- (a) 19,942,766 Consideration Shares will not be subject to voluntary escrow;
  - (b) 25,947,972 Consideration Shares will be subject to 30 days voluntary escrow;
  - (c) 18,534,271 Consideration Shares will be subject to 60 days voluntary escrow;
  - (d) 18,534,257 Consideration Shares will be subject to 90 days voluntary escrow; and
  - (e) 49,992,474 Consideration Shares will be subject to 12 months voluntary escrow.
- Refer to Section 5.5 for a summary of the material terms and conditions of the Share Sale Agreement.
- 4 These figures do not include any Securities that are issued after the date of this Prospectus and are not part of the Offers.

### 3.3 Pro Forma Statement of Financial Position

Set out in Annexure A is an unaudited pro-forma statement of financial position of the Company prepared using the reviewed statement of financial position of the Company as at 31 December 2020 and on the basis of the accounting policies normally adopted by the Company and reflect the changes to its financial position.

The statements of financial position have been prepared to provide information on the assets and liabilities of the Company and pro-forma assets and liabilities of the Company. The historical and pro-forma financial information is presented in an abbreviated form, insofar as it does not include all of the disclosures required by Australian Accounting Standards applicable to annual financial statements.

### 3.4 Effect on control of the Company

The Offers will not have a material impact on the control (as defined by section 50AA of the Corporations Act) of the Company. No investor or existing Shareholder will have a voting power greater than 20% as a result of the completion of the Offers.

### 3.5 Details of substantial holders

Based on publicly available information as at the date of this Prospectus, the persons who (together with their associates) have a relevant interest in 5% or more of the Shares on issue are set out below:

Shareholder	Shares	%
Adrian Floate (and associates) <sup>1</sup>	282,856,614	9.58%

**Notes:**

1. Comprising:
  - (a) 185,578,453 Shares held indirectly by Rare Air Nominees Pty Ltd a company of which Mr Floate is a director;
  - (b) 87,278,161 Shares held directly by Mr Floate; and
  - (c) 10,000,000 Shares held indirectly by Ashleigh Ann Floate and Adrian Jason Floate ATF FAAF Superannuation Fund. Mr Floate is a trustee of the FAAF Superannuation Fund.

The Company does not anticipate any of the Invigo Vendors (or their associates) to have a relevant interest in 5% or more of the Shares on issue following issue of the Consideration Shares.

## 4. RIGHTS ATTACHING TO SHARES

---

### 4.1 Shares

The following is a summary of the more significant rights and liabilities attaching to Shares offered under this Prospectus. This summary is not exhaustive and does not constitute a definitive statement of the rights and liabilities of Shareholders. To obtain such a statement, persons should seek independent legal advice.

Full details of the rights and liabilities attaching to Shares are set out in the Constitution, a copy of which is available for inspection at the Company's registered office during normal business hours.

(a) **Ranking of Shares**

At the date of this Prospectus, all Shares are of the same class and rank equally in all respects. Specifically, the Shares issued upon exercise of the Listed Options will rank equally with existing Shares.

(b) **Voting rights**

Subject to any rights or restrictions, at general meetings: (i) every Shareholder present and entitled to vote may vote in person or by attorney, proxy or representative; (ii) has one vote on a show of hands; and (iii) has one vote for every Share held, upon a poll.

(c) **Dividend rights**

Shareholders will be entitled to dividends, distributed among members in proportion to the capital paid up, from the date of payment. No dividend carries interest against the Company and the declaration of Directors as to the amount to be distributed is conclusive. Shareholders may be paid interim dividends or bonuses at the discretion of the Directors. The Company must not pay a dividend unless the Company's assets exceed its liabilities immediately before the dividend is declared and the excess is sufficient for the payment of the dividend.

(d) **Transfer of Shares**

Shares can be transferred upon delivery of a proper instrument of transfer to the Company or by a transfer in accordance with the ASX Settlement Operating Rules. The instrument of transfer must be in writing, in the approved form, and signed by the transferor and the transferee. Until the transferee has been registered, the transferor is deemed to remain the holder, even after signing the instrument of transfer. In some circumstances, the Directors may refuse to register a transfer if upon registration the transferee will hold less than a marketable parcel.

(e) **General meetings**

Shareholders are entitled to be present in person, or by proxy, attorney or representative to attend and vote at general meetings of the Company. The Directors may convene a general meeting at their discretion. General meetings shall also be convened on requisition as provided for by the Corporations Act.

(f) **Unmarketable parcels**

The Company's Constitution provides for the sale of unmarketable parcels subject to any applicable laws and provided a notice is given to the minority Shareholders stating

that the Company intends to sell their relevant Shares unless an exemption notice is received by a specified date

(g) **Rights on winding up**

The assets of the Company must on a winding up be applied in repayment to members in proportion to their respective holdings.

For personal use only

## 5. ADDITIONAL INFORMATION

---

### 5.1 Company Update

Details of the Company's current activities are set out in the announcements made by the Company to the ASX and are available from the ASX, or the Company's website at [www.cirralto.com.au](http://www.cirralto.com.au).

### 5.2 Nature of this Prospectus

The Shares to be issued pursuant to this Prospectus are continuously quoted securities. This Prospectus is issued under the special prospectus content rules for continuously quoted securities in section 713 of the Corporations Act. This enables listed disclosing entities, such as the Company, to issue a prospectus for continuously quoted securities with modified disclosure requirements if they satisfy certain requirements.

The information in this Prospectus principally concerns the terms and conditions of the Offers and the information reasonably necessary to make an informed assessment of:

- (a) the effect of the Offers on the Company; and
- (b) the rights and liabilities attaching to the Shares offered pursuant to this Prospectus.

The Prospectus is intended to be read in conjunction with the publicly available information in relation to the Company which has been notified to ASX and does not include all of the information that would be included in a prospectus for an initial public offering of securities in an entity that is not already listed on a stock exchange. Investors should therefore also have regard to the other publicly available information in relation to the Company before making a decision whether or not to invest in the Company.

### 5.3 Continuous Reporting and Disclosure Obligations

As the Company is admitted to the official list of ASX, the Company is a "disclosing entity" for the purposes of the Corporations Act. As such, it is subject to regular reporting and disclosure obligations. Specifically, like all listed companies, the Company is required to continuously disclose to the market any information it has which a reasonable person would expect to have a material effect on the price or the value of the Company's securities.

Price sensitive information is publicly released through ASX before it is disclosed to Shareholders and market participants. Distribution of other information to Shareholders and market participants is also managed through disclosure to ASX. In addition, the Company posts information on its website after the ASX confirms an announcement has been made, with the aim of making the information readily accessible to the widest audience.

Investors are encouraged to check and monitor any further announcements made by the Company to ASX prior to securities being issued under the Offer. To do so, please refer to the Company's ASX announcements platform via [www.asx.com.au](http://www.asx.com.au).

By virtue of section 713 of the Corporations Act, the Company is entitled to issue a "transaction-specific" prospectus in respect of the Offer.

In general terms, a "transaction-specific prospectus" is only required to contain information in relation to the effect of the issue of securities on the Company and the rights and liabilities attaching to the securities. It is not necessary to include general information in relation to all of the assets and liabilities, financial position and performance, profits and losses or prospects of the issuing company.

As a disclosing entity under the Corporations Act, the Company states that:

- (a) it is subject to regular reporting and disclosure obligations;
- (b) copies of documents lodged with ASIC in relation to the Company may be obtained from, or inspected at, an office of ASIC; and
- (c) it will provide a copy of each of the following documents, free of charge, to any person on request between the date of issue of this Prospectus and the Closing Date:
  - (i) the annual financial report of the Company for the financial year ended 30 June 2020;
  - (ii) any half-year financial report of the Company lodged with ASIC after the lodgement of the annual financial report referred to above and before the lodgement of this Prospectus with ASIC; and
  - (iii) all continuous disclosure notices given by the Company after the lodgement of the annual financial report referred to above and before the lodgement of this Prospectus with ASIC (see below).

There is no information which has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules that investors or their professional advisers:

- (a) would reasonably require for the purpose of making an informed assessment of:
  - (i) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; and
  - (ii) the rights and liabilities attaching to the securities the subject of this Prospectus; and
- (b) would reasonably expect to find in this Prospectus.

This Prospectus contains information specific to the Offer. If investors require further information in relation to the Company, they are recommended to take advantage of the opportunity to inspect or obtain copies of the documents referred to above.

The following announcements have been lodged with ASX in respect of the Company since the Company lodged its annual financial report for the financial year ended 30 June 2020 on 30 October 2020.

Date	Title
21/07/2021	Reinstatement to official quotation
21/07/2021	Request for reinstatement of trading
16/07/2021	Extended Voluntary Suspension
14/07/2021	Voluntary suspension
12/07/2021	Trading halt
08/07/2021	Cirralto signs Referral Agreement with Fresh Supply Co
07/07/2021	Cirralto signs Referral Agreement with Mastercard
06/07/2021	Trading halt
06/07/2021	Pause in trading

05/07/2021	Proposed issue of securities - CRO
05/07/2021	Binding Share Sale Agreement to Acquire Invigo
05/07/2021	Pause in Trading
23/06/2021	Change of Director's Interest Notice
11/06/2021	S&P DJI Announces June 2021 Quarterly Rebalance
09/06/2021	Change of Director's Interest Notice
08/06/2021	Change of Director's Interest Notice
08/06/2021	Change of Director's Interest Notice
08/06/2021	Change of Director's Interest Notice
04/06/2021	Becoming a substantial holder
04/06/2021	Cirralto Completes Acquisition of Appstablishment
02/06/2021	Appendix 3G
02/06/2021	Appendix 2A
02/06/2021	Cleansing Prospectus
25/05/2021	CIRRALTO INVESTOR WEBINAR
20/05/2021	Results of Meeting
20/05/2021	Investor Presentation
07/05/2021	Appendix 2A
07/05/2021	Prospectus
07/05/2021	Investor Presentation
03/05/2021	Successful Commercial Roll Out of the Spenda Payment Suite
26/04/2021	Quarterly Activities Report
26/04/2021	Appendix 4C – quarterly
23/04/2021	Appendix 2A
19/04/2021	General Meeting Letter to Shareholders
19/04/2021	Notice of General Meeting/Proxy Form
08/04/2021	Appendix 2A
06/04/2021	Strategic Loan Funding Arrangement
23/03/2021	Response to ASX Director's Interest Queries
09/03/2021	Business Payments Launch
05/03/2021	Appendix 2A
04/03/2021	Investor Webinar Presentation
02/03/2021	Change of Director's Interest Notice
02/03/2021	Appendix 3G
01/03/2021	Change of Director's Interest Notice
01/03/2021	Appendix 2A
26/02/2021	Prospectus

26/02/2021	Half Yearly Report & Accounts
26/02/2021	ASX capital raising query
23/02/2021	Investor Presentation
22/02/2021	Proposed issue of Securities – CRO
22/02/2021	Proposed issue of Securities – CRO
22/02/2021	Software Release & BPSP / BPA Testing Update
22/02/2021	Proposed issue of Securities – CRO
22/02/2021	\$18 MILLION PLACEMENT
18/02/2021	Trading halt
17/02/2021	Appendix 2A
16/02/2021	Response to ASX Price Query
15/02/2021	Appendix 2A
11/02/2021	Constitution
04/02/2021	Appendix 2A
29/01/2021	Results of Meeting
28/01/2021	Appendix 4C - quarterly
28/01/2021	Quarterly Activities Report
25/01/2021	Change of Director's Interest Notice
25/01/2021	Appendix 2A
12/01/2021	Response to ASX Price Query
07/01/2021	Appendix 2A
24/12/2020	AGM Letter to Shareholders
24/12/2020	Notice of Annual General Meeting/Proxy Form
18/12/2020	Response to ASX Aware Query
14/12/2020	Cirralto Signs a BPA Agreement with Fiserv and MasterCard
08/12/2020	Investor Presentation
07/12/2020	Reinstatement to official quotation
07/12/2020	Cleansing Prospectus
07/12/2020	BPSP AGREEMENT WITH FISERV AND VISA
03/12/2020	Extension to Voluntary Suspension
30/11/2020	Appendix 2A
30/11/2020	Voluntary suspension
27/11/2020	Appendix 2A
27/11/2020	Proposed issue of Securities - CRO
27/11/2020	Proposed issue of Securities - CRO
27/11/2020	Cirralto Raises \$2.8M via Placement
26/11/2020	Trading Halt

10/11/2020	Appendix 2A
30/10/2020	Annual Report to shareholders

## 5.4 Market Price of Shares and Listed Options

The highest and lowest closing prices of Shares on the ASX during the 3 months preceding the date of this Prospectus, and the closing price on the trading day before the date of this Prospectus, are set out below.

	Price (\$)	Date
Highest	\$0.086	22 April 2021
Lowest	\$0.049	30 June 2021
Last	\$0.058	21 July 2021

The highest and lowest closing prices of listed Options (ASX: CROO) on the ASX during the 3 months preceding the date of this Prospectus, and the closing price on the trading day before the date of this Prospectus, are set out below.

	Price (\$)	Date
Highest	\$0.06	26 April 2021
Lowest	\$0.033	28 and 30 June 2021
Last	\$0.038	21 July 2021

## 5.5 Share Sale Agreement

As set out in the Company's announcement to ASX dated 5 July 2021, the key terms of the Share Sale Agreement between the Company, Invigo and the Invigo Vendors is as follows:

- (a) **(Acquisition):** Subject to satisfaction of certain conditions precedent (as set out below), the Invigo Vendors have agreed to sell and the Company has agreed to purchase, 100% of issued capital of Invigo free from encumbrances.
- (b) **(Consideration):** In consideration for the Acquisition, the Company has agreed to issue to the Invigo Vendors in accordance with their respective ownership interest in Invigo, a total of 132,951,740 Consideration Shares, with those Consideration Shares having:
  - (i) a deemed issue price of approximately \$0.075 per Consideration Share, representing a 20% discount to the VWAP for the 30 trading days prior to the date of execution of the Share Sale Agreement; and
  - (ii) a total value equal to approximately \$10,000,000.
- (c) **(Voluntary Escrow):** Each Invigo Vendor agrees and acknowledges that a proportion of the Consideration Shares will be subject to voluntary escrow (and consents to the imposition by the Company's share registry of a holding lock with respect to those Consideration Shares), as follows:



- For personal use only
- (i) 19,942,766 Consideration Shares will not be subject to voluntary escrow;
  - (ii) 25,947,972 Consideration Shares will be subject to 30 days voluntary escrow;
  - (iii) 18,534,271 Consideration Shares will be subject to 60 days voluntary escrow;
  - (iv) 18,534,257 Consideration Shares will be subject to 90 days voluntary escrow; and
  - (v) 49,992,474 Consideration Shares will be subject to 12 months voluntary escrow.
- (d) **(Conditions Precedent):** Completion of the Share Sale Agreement is subject to and conditional upon satisfaction or waiver (to the extent permitted) of a number of conditions precedent, including (but not limited to) the following:
- (i) the Company notifying the Invigo Vendors it is satisfied with the results of legal, operational and financial due diligence investigations in relation to Invigo, its business and its shares;
  - (ii) no material adverse condition having occurred or arisen in relation to Invigo or its business since execution of the Share Sale Agreement;
  - (iii) each of Andy Hilton and Corrie Hassan entering into employment arrangements with Invigo or the Company, on terms agreeable to the Company;
  - (iv) all security interests over an assets of Invigo being discharged to the reasonable satisfaction of the Company;
  - (v) all applicable change of control consents having been obtained in connection with the Acquisition; and
  - (vi) the Invigo Vendors demonstrating to the reasonable satisfaction of the Company that Invigo will have cleared all, and as at completion have no, outstanding liabilities owing to Invigo's directors.
- (e) **(Termination):** Either party may terminate the Share Sale Agreement if the conditions precedent are not satisfied or validly waived by the Company (as applicable), by 31 August 2021.

As at the date of this Prospectus, all conditions precedent to completion of the Share Sale Agreement have been satisfied. Accordingly, by this Prospectus, the Company the Company invites the Invigo Vendors (or their respective nominees) to apply for a total of 132,951,740 Consideration Shares in accordance with their respective entitlements under the Share Sale Agreement to complete the Acquisition.

Further details regarding the Share Sale Agreement, the Acquisition and Invigo are set out in the Company's announcement to ASX dated 5 July 2021

## 5.6 Litigation

The Directors are not aware of any material legal proceedings which have been threatened or actually commenced against the Company.

## 5.7 Directors' Interests

Other than as set out below or elsewhere in this Prospectus, no Director has, or had within two years before lodgement of this Prospectus with ASIC, any interest in:

- (a) the formation or promotion of the Company;
- (b) property acquired or proposed to be acquired by the Company in connection with its formation or promotion of the Offer; or
- (c) the Offer,

and no amounts have been paid or agreed to be paid (in cash or securities or otherwise) and no benefits have been given or agreed to be given to any Director:

- (a) to induce him to become, or to qualify him as, a Director; or
- (b) for services rendered by him in connection with the formation or promotion of the Company or the Offer.

### **Remuneration**

The remuneration (including superannuation) paid to the Directors for the two financial years prior to the date of this Prospectus, and proposed to be paid to the Directors for the current financial year (on an annualised basis), is set out below:

Director	FY 2019	FY 2020	FY 2021
Peter Richards <sup>1</sup>	\$28,583	\$30,000	\$30,000
Adrian Floate <sup>2</sup>	\$301,125	\$312,168	\$275,000
Stephen Dale <sup>3</sup>	\$30,000	\$30,000	\$30,000
Howard Digby <sup>4</sup>	Nil	\$27,500 <sup>5</sup>	\$30,000

#### **Notes:**

- 1 Peter Richards was appointed as director on 13 December 2017.
- 2 Adrian Floate was appointed as director on 16 June 2015.
- 3 Stephen Dale was appointed as director on 8 April 2014.
- 4 Howard Digby was appointed as director on 30 July 2019.

Further information relating to the remuneration of Directors can be found in the Company's annual financial report for the financial year ended 30 June 2020, which was announced to ASX on 30 October 2020.

### **Securities**

The securities in which the Directors and their associates have or are proposed to have relevant interests in at the date of this Prospectus are set out below:

Director	Shares	Options
Peter Richards <sup>1</sup>	28,386,527	6,659,131 <sup>2</sup>

Adrian Floate <sup>3</sup>	282,856,614	27,650,000 <sup>4</sup>
Stephen Dale <sup>5</sup>	1,694,444	375,000 <sup>6</sup>
Howard Digby <sup>7</sup>	10,616,666	7,091,666 <sup>8</sup>

**Notes:**

- 1 15,144,737 Shares and 3,348,684 listed Options held directly by Mr Richards. 13,241,790 Shares and 3,310,447 listed Options held indirectly by Peter Ian Richards and Carol Richards ATF Richards Family S/F A/C, an entity of which Mr Richards is a trustee and beneficiary.
- 2 6,659,131 listed Options exercisable at \$0.025 on or before 28 July 2023.
- 3 87,278,161 Shares and 14,150,000 listed Options held directly by Mr Floate. 185,578,453 Shares held indirectly by Rare Air Nominees Pty Ltd, an entity of which Mr Floate is a director. 10,000,000 Shares held indirectly by Ashleigh Ann Floate and Adrian Jason Floate ATF FAAF Superannuation Fund, an entity of which Mr Floate is a trustee. 13,500,000 unlisted Options held indirectly by FAAF Pty Ltd ATF Floating Asset Trust> an entity of which Mr Floate has a beneficial interest.
- 4 Comprising 14,500,000 listed Options exercisable at \$0.025 on or before 28 July 2023 and 13,500,000 unlisted Options exercisable at \$0.045 on or before 30 June 2022.
- 5 1,294,444 Shares and 275,000 listed Options held indirectly by Humedale Pty Ltd <Dale Family A/C> (an entity of which Mr Dale is a director) and 400,000 Shares and 100,000 listed Options held indirectly by Stephen Francis Dale & Rudite Rasma Dale <Humedale Super Fund A/C> (an entity of which Mr Dale is trustee).
- 6 Listed Options exercisable at \$0.025 on or before 28 July 2023.
- 7 2,916,666 Shares and 666,666 listed Options held directly by Mr Digby. 7,700,000 Shares, 4,500,000 unlisted Options and 1,925,000 listed Options held indirectly by Lamma Nominees Pty Ltd, an entity of which Mr Digby is a director and shareholder.
- 8 Comprising 2,591,666 listed Options exercisable at \$0.025 on or before 28 July 2023 and 4,500,000 unlisted Options exercisable at \$0.025 on or before 28 July 2023 which remain subject to vesting conditions.

## 5.8 Related Party Transactions

There are no related party transactions entered into that have not otherwise been disclosed in this Prospectus.

## 5.9 Interests of experts and advisors

Other than as set out below or elsewhere in this Prospectus, no underwriter, promoter or any other person named in this Prospectus as performing a function in a professional, advisory or other capacity in connection with the preparation or distribution of the Prospectus holds, or has held within two years before lodgement of this Prospectus with ASIC, any interest in:

- (a) the formation or promotion of the Company; or
- (b) property acquired or proposed to be acquired by the Company in connection with its formation or promotion of the Offer; or
- (c) the Offer,

and no amounts have been paid or agreed to be paid (in cash or Shares or otherwise) to any underwriter, promoter or any other person named in this Prospectus as performing a function in a professional, advisory or other capacity in connection with the preparation or distribution of this Prospectus, for services rendered by that person in connection with the formation or promotion of the Company or the Offer.

Nova Legal has acted as the solicitors to the Company in relation to the Offer. The Company estimates it will pay Nova Legal \$5,000 (excluding GST and disbursements) for these services. During the 24 months preceding lodgement of this Prospectus with the ASIC, Nova Legal has been paid fees totalling approximately \$51,308 (including GST and disbursements).

## 5.10 Consents

Each of the parties referred to in this Section:

- (a) does not make, or purport to make, any statement in this Prospectus other than those referred to in this Section; and
- (b) to the maximum extent permitted by law, expressly disclaims and takes no responsibility for any part of this Prospectus other than a reference to its name and a statement included in this Prospectus with the consent of that party as specified in this Section.

Nova Legal has given its written consent to being named as solicitors to the Company in this Prospectus. Nova Legal has not withdrawn its consent prior to lodgement of this Prospectus with ASIC.

## 5.11 Estimated Expenses of the Offers

The estimated expenses of the Offers (excluding GST) are as follows:

Item	Amount (\$)
ASIC fees	\$3,206
ASX fees	\$22,582
Legal fees	\$5,000
Miscellaneous expenses	\$1,794
<b>Total</b>	<b>\$32,582</b>

## 5.12 Electronic Prospectus

Pursuant to ASIC Regulatory Guide 107, ASIC has exempted compliance with certain provisions of the Corporations Act to allow distribution of an electronic prospectus on the basis of a paper prospectus lodged with ASIC, and the publication of notices referring to an electronic prospectus, subject to compliance with certain conditions.

If you have received this Prospectus as an electronic Prospectus, please ensure that you have received the entire Prospectus. If you have not, please contact the Company and the Company will send you, for free, either a hard copy or a further electronic copy of the Prospectus or both.

The Company reserves the right not to accept an Application Form from a person if it has reason to believe that when that person was given access to the electronic Application Form, it was not provided together with the electronic Prospectus and any relevant supplementary or Prospectus or any of those documents were incomplete or altered.

## 6. DIRECTOR'S CONSENT

---

This Prospectus is dated 22 July 2021 and is issued by Cirralto Limited.

The Directors have made all reasonable enquires and on that basis have reasonable grounds to believe that any statements made by the Directors in this Prospectus are not misleading or deceptive.

This Prospectus is prepared on the basis that certain matters may reasonably be expected to be known to likely investors or their professional advisors.

Each of the Directors of Cirralto Limited has consented to the lodgement of this Prospectus in accordance with section 720 of the Corporations Act and has not withdrawn that consent.

Signed for and on behalf of Cirralto Limited:



---

**Peter Richards**  
**Chairman**

## 7. DEFINITIONS

---

**Acquisition** has the meaning given in Section 1.1.

**AEST** means Australian Eastern Standard Time.

**Applicant** means an investor who applies for Shares pursuant to the Offers.

**Application Form** means an application form attached to or accompanying this Prospectus.

**ASIC** means the Australian Securities and Investments Commission.

**ASX** means ASX Limited (ABN 98 008 624 691) operating as the Australian Securities Exchange.

**Business Day** means any day which is defined to be a Business Day pursuant to Listing Rule 19.12 of the Listing Rules.

**CHESS** means Clearing House Electronic Sub-register System of ASX Settlement Pty Ltd (ACN 008 504 532).

**Cleansing Offer** means the offer of up to 10,000 Shares pursuant to this Prospectus for the purpose of removing any trading restrictions attaching to Shares issued prior to the Closing Date.

**Closing Date** means the closing date of the Offer being 5.00pm AEST on 29 July 2021 (unless extended).

**Company** means Cirralto Limited (ACN 099 084 143).

**Consideration Shares** has the meaning given in Section 1.1.

**Constitution** means the Company's Constitution as at the date of this Prospectus.

**Corporations Act** means the *Corporations Act 2001* (Cth).

**Cth** means the Commonwealth of Australia.

**Directors** means directors of the Company.

**Dollars** or **\$** means dollars in Australian currency.

**GST** means goods and service tax levied in Australia pursuant to A New Tax System (Goods and Services Tax) Act 1999 (Cth).

**Invigo** means Invigo Pty Ltd (ACN 622 520 450).

**Invigo Vendors** means the shareholders of Invigo.

**Listing Rules** means the Listing Rules of the ASX.

**Offers** means the Vendor Offer and the Cleansing Offer.

**Opening Date** means the opening date of the Offer being 22 July 2021.

**Option** means an option to acquire a Share.

**Prospectus** means this prospectus dated 22 July 2021.

**Quotation** and **Official Quotation** means official quotation on ASX.

**Securities** means Shares and/or Options.

**Share** means a fully paid ordinary share in the capital of the Company and includes the Considerations Shares (unless the context otherwise requires).

**Shareholder** means the holder of a Share as recorded in the register of the Company.

**Share Sale Agreement** has the meaning given in Section 1.1

**Share Registry** means the share registry of the Company as specified in the corporate directory of this Prospectus.

**Vendor Offer** means the offer of up to 132,951,740 Consideration Shares to the Invigo Vendors (or their respective nominees) pursuant to this Prospectus in consideration for the Acquisition.

For personal use only

## Annexure A– Pro-Forma Statement of Financial Position

### Pro-Forma Statement of Financial Position as at 31 December 2020

#### Cirralto Limited Proforma Statement of Financial Position

	<b>Cirralto Limited</b>	<b>Material Proforma adjustments</b>	<b>Effect of the Invigo acquisition</b>	<b>Proforma Balance Sheet</b>
	<b>As at 31-Dec-20</b>	<b>As at 31-Dec-20</b>	<b>As at 31-Dec-20</b>	<b>As at 31-Dec-20</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
<b>Assets</b>				
<b>Current assets</b>				
Cash and cash equivalents	3,950,798	16,410,398	1,023,804	<b>21,385,000</b>
Trade and other receivables	534,239	(427,824)		<b>106,415</b>
R&D Refund	-	1,733,333		<b>1,733,333</b>
Financial Assets		1,955,977	3,759,348	<b>5,715,325</b>
Other current assets	1,321,424	(311,000)	35,541	<b>1,045,965</b>
<b>Total current assets</b>	<b>5,806,461</b>			<b>29,986,037</b>
<b>Non-current assets</b>				
Property, plant & equipment	9,335	1,509	4,270	<b>15,114</b>
Right-of-use asset	29,451			<b>29,451</b>
Intangible assets - software IP	-	8,854,634	190,531	<b>9,045,165</b>
Intangible assets - ASG goodwill	-	51,873,813		<b>51,873,813</b>
Intangible assets - Invigo goodwill			9,664,207	<b>9,664,207</b>
<b>Total non-current Assets</b>	<b>38,786</b>			<b>70,627,751</b>
<b>Total Assets</b>	<b>5,845,247</b>			<b>100,613,788</b>
<b>Liabilities</b>				
<b>Current liabilities</b>				
Trade and other payables	694,557	1,904,211	106,232	<b>2,705,000</b>
Payroll related liabilities	-	895,001		<b>895,001</b>
Lease liability	28,474			<b>28,474</b>
Provisions	73,857	2,396,447		<b>2,470,304</b>
Financial liabilities			4,571,468	<b>4,571,468</b>
Other loans	-	42,889		<b>42,889</b>
<b>Total current liabilities</b>	<b>796,888</b>			<b>10,713,137</b>



<b>Total Liabilities</b>	796,888			<b>10,713,137</b>
<b>Net assets</b>	5,048,359			<b>89,900,651</b>
<b>Equity</b>				
Contributed equity	67,673,225	80,848,239	10,000,000	<b>158,521,464</b>
Reserves	4,641,047	4,079,591		<b>8,720,638</b>
Accumulated losses	(66,001,284)			<b>(66,001,284)</b>
Current period loss	(1,264,629)	(10,075,538)		<b>(11,340,167)</b>
<b>Total equity</b>	5,048,359			<b>89,900,651</b>

The above pro-forma unaudited consolidated statement of financial position is based on the reviewed statement of financial position of the Company and its controlled entities for the half-year ended 31 December 2020 adjusted for the following material changes subsequent to that date:

1. Completion of \$18m placement in February 2021.
2. Payment of \$500,000 pursuant to the Business Payments Solution Provider Agreement with Fiserv (NASDAQ: FISV).
3. Completion of the acquisition of Appstablishment Software Group Pty Ltd, as announced on 20 May 2021.
4. Repayment of related party loan by the issue of shares and options, as announced to ASX on 20 May 2021.
5. Recognition of estimated R&D refund for FY21.
6. Expense of prepayments for the 6 month period ended 30 June.
7. Exercise of options over the 6 month period and the issue of unlisted and listed options to corporate advisors as fees for placement as announced to ASX in February 2021.
8. Reclassification of liability balances of Appstablishment on acquisition.
9. Loan payments made to Invigo Pty Ltd as part of facility arrangement announced in April 2021.
10. Recognition of material working capital payments over the 6 month period.